IntroDuctIon
Antigen presentation is an innate immune function that is crucial in self/non-self discrimination and in the pathogenesis of most immune-mediated diseases. The chief immune cells endowed with this function, also known as professional antigen-presenting cells (APCs), include dendritic cells (DCs), macrophages, monocytes and B lymphocytes. DCs, macrophages and monocytes, including immature monocytes, are particularly competent in antigen capturing and presentation, and in activating antigen-specific T-cell responses through major histocompatibility complex class II (MHC II) molecules [1] [2] [3] [4] [5] [6] [7] . MHC II molecules are encoded in the highly genetically polymorphic human leukocyte antigen (HLA) region that produces multiple molecules required for antigen presentation, including HLA-DR, a MHC II molecule predominantly and abundantly expressed by APCs. As APCs contribute crucially to the pathogenesis of a range of diseases, detailed characterization of their functional status would be valuable in devising strategies for diagnosis, immunological monitoring and therapy, and would furnish important insight into the mechanisms of APC mobilization. More generally, the human immune system is poorly understood 8, 9 , and there is an urgent need to improve our knowledge using the latest technologies.
Phenotypic characterization of APCs has been hampered by the large number of surface markers required to identify a subpopulation or subset, and furthermore, limitations of conventional three-to four-color flow cytometers are major drawbacks 1, 10, 11 . Advantages of single-cell immunophenotyping of blood APCs by flow cytometry have been showed and proven feasible 12 , offering relatively high sensitivity and statistical power compared with nonflow-based technologies. In addition, polychromatic ( > six colors) flow cytometry increases the data-capturing throughput and enables concurrent, multiplexed analysis of cell subsets and populations in the same reaction tube (e.g., calculation of percentages or ratios of cell subsets, parallel comparison of surface expression density of a molecule between two cell populations), as well as a qualitative assessment and characterization of the functional status of cells 13, 14 . In conjunction with the use of minimally manipulated leukocytes derived from erythrocyte-lysed fresh blood sample, instead of density-gradient-enriched mononuclear cells, immunophenotypic data can be captured with a minimal introduction of artifacts or factors that affect immunostaining 15 . Selection and rigorous testing of monoclonal antibodies and fluorochromes are crucial to successful polychromatic flow cytometry. Recently, Jansen et al. 16 reported an eight-color immunostaining protocol for flow cytometry that uses MHC II, CD14, CD11c and CD123 with/without CD19 as cell-subset-defining markers. Our early experience with eight-color flow cytometry using six subset-defining monoclonal antibodies concomitantly (targeting CD14, CD16, CD19, CD11c, CD123 and HLA-DR) indicated that an accurate definition of DC subsets is better achieved using the stringent Lineage cocktail 1 (Lin1)-fluorescein isothiocyanate (FITC)-negative selection markers or antibodies (BD Biosciences) that target CD3, CD14, CD16, CD19, CD20 and CD56; these lineage markers are all undetectable on the two major DC subsets. In other words, a lack of expression of Lin1 effectively excludes T lymphocytes, CD14 + monocytes, CD14 + CD16 + monocytes, CD16 + monocytes, polymorphonuclear neutrophils, B lymphocytes and natural killer cells. Moreover, CD11c (integrin α X ) and CD123 (IL-3 receptor-α), without the exclusion of lineage markers, are not DC-specific as they are expressed by various myeloid and lymphoid cells.
Therefore, to maximize the capabilities of an eight-color flow cytometer (BD LSR II with blue, red and violet lasers) while preserving the accurate identification of monocyte subsets, B lymphocytes and DC subsets, in addition to retaining the capacity to analyze three to four target molecules of interest, we have devised two protocols with similar workflow, protocols A and B (Fig. 1) , that have undergone testing and ascertainment. The two immunostaining protocols are modular and can be easily carried out in parallel, or independently, to define the major circulating APC subsets in whole blood, namely, CD14 + , CD14 + CD16 + and CD16 + monocytes; CD19 + HLA-DR + B cells; and myeloid (MDCs or preDC1) and plasmacytoid (PDCs or preDC2) DCs.
Performing both protocols concurrently can reduce the elapsed time from phlebotomy to immunostaining ('arm-to-antibody' time) and minimize any potential time-dependent in vitro confounding effects when studying innate cellular attributes that are intrinsically volatile. The use of predeveloped, standardized fluorescent beads for normalization of fluorescence intensity data as well as for periodic fine-tuning of the flow cytometer 17, 18 can reduce nonbiological and/or instrumental variation arising from day-to-day operation of the flow cytometer, especially for multicenter and/or longitudinal immunophenotyping studies.
Monocytes are progenitors for macrophages and certain DCs, and two principal subpopulations have been described, namely, CD14 + HLA-DR + ('inflammatory') and CD16 + HLA-DR + ('resident') monocytes 19, 20 6, [21] [22] [23] . Even in the absence of an exogenous stimulus, the CD14 + CD16 + subset differentiates within 12 h from CD14 + monocytes, and therefore, we recommend proceeding with the immunostaining within 4 h of blood donation and to rotate the blood collection tubes, if possible, to avoid subsequent miscalculation of monocyte subset ratios and changes in the expression levels of certain surface molecules (Fig. 3) .
MDCs and PDCs derive from different hematopoietic lineages and have divergent physiological functions 7, [24] [25] [26] [27] [28] [29] . In conjunction with positive expression of MHC II molecules such as HLA-DR and the absence of Lin1 markers, MDCs and PDCs can be further classified as Lin1 − HLA-DR + CD11c + and Lin1 − HLA-DR + CD123 + , respectively. CD303 (BDCA-2) can be used alternatively to identify PDCs, whereas CD1c + (BDCA-1) and CD141 + (BDCA-3 or thrombomodulin) are markers that identify additional MDC subsets [30] [31] [32] . CD303 is a PDC-specific C-type lectin involved in antigen uptake, processing and presentation to T cells, and regulates type I interferon release, a cell-defining attribute of PDCs 33 . Neutrophils can be identified and distinguished from monocytes, macrophages and DCs by virtue of their high FSC and SSC 11 -thus, the use of a different gating strategy (see also Fig. 2a ) and immunophenotypic profile: CD16 high CX 3 CR1 − CD62L + CD11b high . In line with recent findings, neutrophils differentiate from the CX 3 CR1-negative lineage of myeloid progenitors that diverge from the macrophage-DC precursors early in hematopoiesis 29 . Investigators interested in this cell population can maximize the yield of immunophenotyping data by gating on the granulocyte cluster (Fig. 2a) .
Protocol A details the use of eight fluorochrome-conjugated monoclonal antibodies (or 10 parameters) to characterize CD14 + , CD14 + CD16 + and CD16 + monocytes and B-cell surface expression of chemokine receptors (e.g., CX 3 CR1 or fractalkine receptor, CCR2), adhesion molecules (e.g., CD11b or integrin-α M , CD62L or L-selectin) and co-stimulatory/accessory antigen presentation molecules (e.g., CD83, CD86, CD209 or DC-SIGN) in whole blood. Determination of monocyte subset ratios is also shown. Protocol B takes advantage of the Lin1 immunostaining strategy, focusing on the identification of CD11c + MDCs and CD123 + PDCs, with demonstration of the alternative and/or concomitant use of the DC markers CD1c and CD303 in combination with Lin1 − HLA-DR + to ascertain the identity of MDCs and PDCs, respectively. Specific to this protocol is the use of a violet-laserexcitable fluorochrome, particularly Pacific Blue (peak excitation/ emission of ~410/455 nm) or an equivalent, such as eFluor 450 (peak excitation/emission of ~405/450 nm), conjugated with anti-CD123 antibody that opens up other commonly used channels (e.g., phycoerythrin (PE), Alexa Fluor 700 and APC-Alexa Fluor 750) for use.
Isotype control immunoglobulins are not needed for quantitative immunophenotyping 18 . In a recent large-scale, gene immunophenotyping study of nearly 200 individuals that we carried out 14 , we eliminated the use of the isotype controls after ascertaining beforehand that the monoclonal antibodies are specific. Isotype control immunoglobulins are liable to fluctuate over time, and the use of fluorescent microspheres is a solution to the time-dependent effects or variability observed in longitudinal studies 18 . We recommend only the initial use of isotype-matched control immunoglobulins to establish that a target antibody is specific, and then proceed to longitudinal immunophenotyping using fluorescent microspheres to normalize the acquired data. When performing large-scale, quantitative immunophenotyping by polychromatic flow cytometry over a prolonged period (i.e., on the order of months), the investigator should have a precise hypothesis a priori, determine the power of the study and calculate the sample size required, in order to enable estimation of the amount of antibodies and reagents required. Apart from instrumental variation that can be remedied using standardized fluorescent microspheres 18 , a batch-to-batch effect of reagents is probably another major source of variability. In a carefully planned study with a known number of immunostaining reactions, the investigator can then order an oversized batch and pool the antibodies to circumvent batch variation.
Each immunostaining reaction requires as little as 50-100 µl of fresh whole blood without prior density-gradient separation. This method provides a cost-effective, practical approach to highthroughput polychromatic immunophenotyping of the major APC subsets in whole blood and serves as a framework on which to incorporate additional analysis parameters, depending on the flow cytometer setup and fluorochromes used. and HLA-DR. Histograms illustrate B-cell expression profiles of (h) CX 3 CR1, CCR2 and CD11b, and (i) CD86, CD209, CD83 and CD62L in parallel to monocytes co-immunostained in the same reactions. (j) Functionality of the anti-human CD209 antibody in PerCP-Cy5.5 is shown in a separate reaction by activation of peripheral whole blood with IL-1β (10 ng ml − 1 ), TNF-α (50 ng ml − 1 ), IFN-γ (1000 U ml − 1 ; Peprotech) and ultra-pure lipopolysaccharide (100 ng ml − 1 ; InvivoGen); cells in the monocyte gate expressing CD11c and HLA-DR are shown.
MaterIals

REAGENTS
Fresh whole blood from consenting healthy human donors ! cautIon Universal precaution must be taken and experiments must be carried out in category 2 biological safety cabinets; where possible, screened blood must be used and bio-hazardous waste must be disposed as per local institutional protocol. ! cautIon All experiments using human tissue must conform to the national and institutional regulations.
• Citrate phosphate dextrose adenine (CPDA)-pretreated blood collection tubes (Greiner bio-one, cat. no. 455094; Sarstedt, cat. no. 01.1610.001)  crItIcal Our testing of multiple lots of CPDA and sodium heparin tubes indicated that the former did not contain endotoxin levels above the detection limit of the assay, whereas the latter had more variable background levels of endotoxin (range < 0.01-1.04 EU ml − 1 , n = 10, total number of tubes tested from at least four lots); indicators of increased Table 1 ) ! cautIon Sodium azide is a preservative present in most antibody preparations that is irritating to the skin and can be explosive when accumulated in plumbing; flush and dispose it with copious amounts of water. Even though azide is present, to avoid microbial contamination, open the vials containing antibody in a laminar flow hood and remove aliquots using sterile pipette tips.  crItIcal Before starting a longitudinal, quantitative immunophenotyping study, perform a titration analysis to determine the saturating amount or concentration of each antibody required to ensure maximal coverage of the expressed target antigen in order to attribute any variation observed to true biological differences. This can be performed by using incremental doses of a single antibody in order to immunostain a donor's blood samples under the same experimental conditions and determine the dose required to obtain a plateau of fluorescence intensity by constructing a line plot of antibody concentration versus mean (or median) fluorescence intensity, in conjunction with overlaid curves displayed histographically 34 . The optimal concentration is usually the one at the beginning of a saturation plateau 34 . For markers not requiring absolute quantitation in a study, to reduce cost, adequate staining can be often obtained with less than a saturating amount of antibody. Isotype control immunoglobulins (see Table 1 Step 3B) or use manufacturer-preconjugated anti-CD123-eFluor 450 (eBioscience), thereby obviating the conjugation procedure detailed in
Step 3Biii. Store all antibodies at 4 °C. Table 1 ). When frequent, in-house calibration and fine-tuning of flow cytometer as detailed by Perfetto et al. 17 is not possible, regular (quarterly) evaluation and servicing of the flow cytometer by the manufacturer should be scheduled. ! cautIon Internal components of a flow cytometer pose serious health hazards and should not be tampered with by unqualified personnel.
EQUIPMENT SETUP Flow cytometer
• proceDure preparation of reagents • tIMInG 30 min 1| Label 2.0-ml microcentrifuge tubes.  crItIcal step 1.5-ml microcentrifuge tubes can be used if reaction volumes are scaled down proportionately. However, the yield of rare cell populations might be low. When working with large numbers of staining reactions, 2-ml 96-well Polypropylene Deep-Well Plates in conjunction with adhesive sealing film are useful; avoid contact of blood sample with the adhesive surface. It is not recommended to use polystyrene FACS tubes for immunostaining APCs, as these cells might become activated by the surface substrate. When polypropylene FACS tubes are used, exercise care when discarding the supernatant, as the pellet can be difficult to visualize. Use sterile plasticware. 6| While the antibodies of protocol A and protocol B are allowed to incubate with blood samples, perform single-color staining for later fluorochrome spectral overlap compensation by applying the same, single antibody that was used in the master mixture for each individual fluorochrome. Incubate samples in the dark for 30 min at 15-20 °C. Omit this step when using standardized fluorescence-labeled microspheres for setting spectral compensation (see also PROCEDUREAcquisition).  crItIcal step Performing single-color staining for all fluorochromes each time when immunophenotyping is performed can also serve as a quality control, and help to troubleshoot and gauge the quality of the antibody and the staining. 
9|
Carefully pipette out and discard the supernatant. Resuspend the cell pellet in 1.0 ml of cold, endotoxin-free 1× PBS for each 100 µl of whole blood sample used and mix well.  crItIcal step Perform all subsequent steps at 4 °C.
10|
Centrifuge at 350g for 7 min at 4 °C. 15| Determine fluorochrome pair compensations by first acquiring samples from single fluorochrome-antibody staining. Use bi-exponential (or 'Logicle') display of x axis and y axis when determining the amount of compensation 35 . Set compensation now or after collection of all samples, depending on capabilities of flow cytometer and software capabilities; automatic compensation might be available on some platforms. An orderly workflow, including the systematic organization of bivariate plots displaying antibody-fluorochrome pairs, is essential to successful polychromatic flow cytometry (Fig. 4) . For literature on flow cytometry instrument setup and fluorochrome compensation, investigators are referred to excellent reviews published by others 10, [33] [34] [35] [36] [37] [38] [39] .  crItIcal step Each target antigen can have a drastically different cell-surface distribution and biophysical properties, requiring configuration of a unique set of fluorochrome compensation values. Use an abundantly expressed surface epitope when setting compensation. (Fig. 2a, pink enclosure) and drill down to produce a one-dimensional histogram for HLA-DR-PerCP (Fig. 2b) .
11|
(ii) Select HLA-DR + cells (Fig. 2b , within the pink gate) and use a quantile contour (zebra) plot to display expression of CD14-Pacific Orange versus CD16-Pacific Blue. (iii) Gate on discrete clusters of CD16 + (resident), CD14 + CD16 + and CD14 + (inflammatory) monocytes (Fig. 2c) . Leave Fig. 2e). 
(B) B lymphocytes
(i) Place gate around the lymphocyte cluster on the FSC versus SSC plot (Fig. 2f) , drill down on this population and create a CD19-Alexa Fluor 700 versus HLA-DR-PerCP (Fig. 2g) . HLA-DR-expressing B cells are CD19 + HLA-DR + . PE, APC, APC-Alexa Fluor 750 and FITC or PerCP/PerCP-Cy5.5 are fluorochrome channels left available for quantification of antigen expression levels and are displayed histographically (Fig. 2h) . PerCP or PerCP-Cy5.5 can be used as the quantification channel when HLA-DR-FITC instead of HLA-DR-PerCP is used (Fig. 2i) (Fig. 5b , pale-blue box).
(ii) Using a CD11c-APC versus CD123-Pacific Blue plot, calculate the MDC:PDC ratio or percentage (Fig. 5c) . (iii) To determine the expression levels of target molecules for both DC subsets, create two-dimensional scatter plots from the Lin1 − HLA-DR + cluster (Fig. 5b, pale-blue box) , generating CD11c versus HLA-DR (for CD11c + HLA-DR + MDCs) and (Fig. 5d) , from which histograms displaying expression levels of molecules in the PE, APC-Alexa Fluor 750 and Alexa Fluor 700 channels can be created (Fig. 5e and 5f) antIcIpateD results Protocol A: The gating of monocytes on a FSC versus SSC bivariate plot is important for identifying the monocyte subsets that have different sizes and granularity 1, 2 . CD16 + monocytes have lower FSC and SSC, and are situated close to the lymphocyte cluster (Fig. 2a, green oval) , whereas CD14 + monocytes, owing to their larger numbers, size (higher FSC) and higher cytoplasmic granularity (higher SSC), cluster near granulocytes (Fig. 2a, red oval) . The former subset can be missed or its percentages underestimated if the gating is too conservatively placed on only the latter subpopulation. Within the monocyte gate, HLA-DR + cells (Fig. 2b) are separated based on expression of CD14 and CD16, and are displayed on a [40] [41] [42] . Another analysis of monocyte subsets and CD19 + HLA-DR + B cells is shown by CD86-PE, CD83-APC and CD209-PerCP-Cy5.5 through use of HLA-DR-FITC instead of HLA-DR-PerCP (Fig. 2) . Although the expression of CD209 is negligible or undetectable on resting monocytes, circulating monocytes and HLA-DR + CD19 + B cells from a healthy blood donor ( Fig. 2e and 2i) , the functionality of this fluorochrome-labeled antibody is shown by its increased expression on CD11c + HLA-DR + cells in the monocyte gate following cytokine activation (Fig. 2j) . We advise immunostaining within 4 h of blood donation, as changes in the monocyte subset dynamics occur with time (Fig. 3) . Protocol A uses ten parameters or eight fluorochromes (FITC, PE, PerCP or PerCP-Cy5.5, Alexa Fluor 700, APC, APC-Alexa Fluor 750, Pacific Orange and Pacific Blue).
Protocol B: This protocol is a modification of the four-color staining reported by Willmann et al. 12 and others. Because four fluorochrome channels (typically, Lin1-FITC, HLA-DR-PerCP, CD11c-APC and CD123-PE) are required for separating MDCs and PDCs, this limitation precludes the use of antibodies of interest that are commonly available in PE and APC. Using a three-laser flow cytometer (BD LSR II) and a violet-laser-excitable fluorochrome (e.g., anti-CD123 conjugated with Pacific Blue), we were able to maximize immunostaining combinations and attain seven-color multiplexed analysis of two major blood DC subsets. There exist future opportunities for robust eight-color analyses with the increased availability of (Fig. 5d) . CD1c and CD303 are alternative markers that can identify Lin1 − HLA-DR + MDC and PDC, respectively, ( Fig. 6a and b) but should not be regarded as equivalent to CD11c and CD123 in view of the tremendous DC heterogeneity 26, 27, [30] [31] [32] 44 . MDC:PDC ratios or percentages (Fig. 5c) have been reported to alter in disease states; however, gating strategies and the use of DC-defining markers can vary between studies 45, 46 . The CD11c-CD123 bivariate plot of Lin1 − HLA-DR + cells (Fig. 5c and 5a , top row) is a common strategy used to simultaneously display ratios between the two DC subsets 44, 45 . For quantification of expression levels (i.e., in mean or median fluorescence intensity units), we find that the CD11c + HLA-DR + and CD123 + HLA-DR + plots (Fig. 5d ) generated from Lin1 − cells (Fig. 5b , pink box) are preferable, as they provide a clear visualization of DC clusters (Fig. 5d , orange and purple boxes) and other cells or events; this is also the method shown in the product sheet provided by the manufacturer of the Lin1 mixture antibodies (BD Biosciences). Protocol B has the capacity for at least nine parameters or seven fluorochromes (FITC, PE, PerCP, APC, APC-Alexa Fluor 750, Alexa Fluor 700, Pacific Blue). Using CD101 expression profiling of circulating DCs as an example (Fig. 5f) , we have concurrently identified positive CD101 surface expression on MDCs, but non-expression on PDCs, as a novel strategy for differentiating the two DC subsets, findings that might have implications also in their differential immunomodulatory functions 31, [47] [48] [49] [50] 52 . Surface markers useful for the identification of circulating APC subsets are summarized in table 3. As the complexity of polychromatic flow cytometry increases, multidimensional analyses of the data by computational modeling might one day replace manual gating and increase the throughput and objectivity of analyses 53 . Comprehensive information on flow cytometer setup, fluorochromes, spectral overlap compensations, fluorescent bead normalization for longitudinal immunophenotyping studies, operational pitfalls and other useful technical information are detailed elsewhere 10, 18, [34] [35] [36] [37] [38] [39] . Further links to major manufactures of flow cytometers, accessories and fluorochrome-conjugated antibodies can be found at the end of an article by Perfetto et al. 
